Your session is about to expire
← Back to Search
Enhanced Emergency Care for Sickle Cell Crisis (SCIENCE Trial)
N/A
Recruiting
Led By David Brousseau, MD, MS
Research Sponsored by Medical College of Wisconsin
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Diagnosis of sickle cell disease
Receipt of at least one opioid
Must not have
Priapism
Sickle cell trait
Timeline
Screening 3 weeks
Treatment Varies
Follow Up a maximum of about 6 hours as all opioids received during the ed stay will be captured
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a care pathway to see if it increases guideline adherent care for children in the emergency department who have sickle cell disease and are in acute pain.
Who is the study for?
This trial is for children with Sickle Cell Disease (SCD) who visit the emergency department due to a pain crisis and have received at least one opioid. It's not for those with fever over 38.5°C, priapism, sickle cell trait, or acute chest syndrome during their ED visit.
What is being tested?
The study tests a care pathway designed to ensure that children with SCD receive timely and guideline-adherent pain management in the emergency department. The goal is to reduce hospitalizations and improve quality of life by adhering to established pain management guidelines.
What are the potential side effects?
Since this trial focuses on implementing a care pathway rather than testing new medications, there are no direct side effects from interventions being studied. However, general risks associated with opioid use may still apply.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been diagnosed with sickle cell disease.
Select...
I have taken opioids at least once.
Select...
I visited the ER for a pain crisis that didn't have complications.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have experienced prolonged erections.
Select...
I have sickle cell trait.
Select...
I have had acute chest syndrome.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ a maximum of about 6 hours as all opioids received during the ed stay will be captured
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~a maximum of about 6 hours as all opioids received during the ed stay will be captured
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Timeliness of receipt of opioids
Secondary study objectives
Median time to opioids
Percent of children hospitalized
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Active Control
Group I: Post-interventionActive Control1 Intervention
Group II: Delayed interventionActive Control1 Intervention
Find a Location
Who is running the clinical trial?
Nemours Children's Health SystemOTHER
9 Previous Clinical Trials
12,068 Total Patients Enrolled
Medical College of WisconsinLead Sponsor
631 Previous Clinical Trials
1,176,630 Total Patients Enrolled
Pediatric Emergency Care Applied Research NetworkNETWORK
5 Previous Clinical Trials
8,025 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have been diagnosed with sickle cell disease.I have taken opioids at least once.I visited the ER for a pain crisis that didn't have complications.I have experienced prolonged erections.I have sickle cell trait.I have had acute chest syndrome.
Research Study Groups:
This trial has the following groups:- Group 1: Post-intervention
- Group 2: Delayed intervention
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger